Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Bancroft

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Patient Preference and Adherence|July 18, 2015
Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care settingPuja P Khanna, Aki Shiozawa, Valery Walker, et al.
Allergy and Asthma Proceedings|September 2, 2020
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data baseHector Ortega, Beth Hahn, Michael Bogart, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2024
Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasonsIan McGovern, Benjamin Chastek, Tim Bancroft, et al.
Journal of Medical Economics|February 1, 2013
Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured populationDaniel E Furst, Ann Clarke, Ancilla W Fernandes, et al.
Molecular Biosystems|June 5, 2012
Differential accumulation of host mRNAs on polyribosomes during obligate pathogen-plant interactionsJackson R Moeller, Matthew J Moscou, Tim Bancroft, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 14, 2025
Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza seasonMahrukh Imran, Benjamin Chastek, Tim Bancroft, et al.
Current Medical Research and Opinion|September 16, 2022
Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosisMindie H Nguyen, Lewis R Roberts, Nicole M Engel-Nitz, et al.
Population Health Management|May 12, 2020
Hepatitis C Screening Rates and Care Cascade in a Large US Insured Population, 2010-2016: Gaps to EliminationJosephine Nhu Tran, Robert J Wong, Janet S Lee, et al.
Inflammatory Bowel Diseases|November 3, 2023
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARYNoa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Managed Care (Langhorne, Pa.)|February 17, 2018
Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured PopulationDouglas Ca Taylor, Jessica L Abel, Tim Bancroft, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Patient Preference and Adherence|July 18, 2015
Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care settingPuja P Khanna, Aki Shiozawa, Valery Walker, et al.
Allergy and Asthma Proceedings|September 2, 2020
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data baseHector Ortega, Beth Hahn, Michael Bogart, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2024
Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasonsIan McGovern, Benjamin Chastek, Tim Bancroft, et al.
Journal of Medical Economics|February 1, 2013
Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured populationDaniel E Furst, Ann Clarke, Ancilla W Fernandes, et al.
Molecular Biosystems|June 5, 2012
Differential accumulation of host mRNAs on polyribosomes during obligate pathogen-plant interactionsJackson R Moeller, Matthew J Moscou, Tim Bancroft, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 14, 2025
Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza seasonMahrukh Imran, Benjamin Chastek, Tim Bancroft, et al.
Current Medical Research and Opinion|September 16, 2022
Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosisMindie H Nguyen, Lewis R Roberts, Nicole M Engel-Nitz, et al.
Population Health Management|May 12, 2020
Hepatitis C Screening Rates and Care Cascade in a Large US Insured Population, 2010-2016: Gaps to EliminationJosephine Nhu Tran, Robert J Wong, Janet S Lee, et al.
Inflammatory Bowel Diseases|November 3, 2023
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARYNoa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, et al.
Managed Care (Langhorne, Pa.)|February 17, 2018
Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured PopulationDouglas Ca Taylor, Jessica L Abel, Tim Bancroft, et al.
Pageof 5